港股创新药股接力大爆发，华昊中天医药3日飙涨95%

Group 1 - The core viewpoint of the news is that the innovative drug sector in the Hong Kong stock market is experiencing a significant surge, with several companies seeing substantial stock price increases, particularly Huahao Zhongtian Pharmaceutical, which saw its stock price double in just three trading days [1][2][3] - Huahao Zhongtian Pharmaceutical has emerged as a standout performer, with a stock price increase of 55% on July 3 and a total increase of 95% by July 4, driven by its focus on developing innovative cancer drugs [2][3] - Other notable companies in the innovative drug sector include Rongchang Biopharmaceutical, which rose approximately 15% after licensing global development rights for a drug for $4.23 billion, and Basestone Pharmaceuticals, which saw a stock price increase of over 13% after disclosing new drug candidates [3][6] Group 2 - The first half of 2025 is expected to witness a wave of new listings in the Hong Kong biopharmaceutical market, with 10 companies successfully listing, most of which are innovative drug firms [4][5] - Newly listed innovative drug companies have shown impressive performance, with Yingen Biopharmaceutical's stock price soaring by 193.23% since its April 15 listing, and Yaojie Ankang's stock price increasing by 158.17% since its June 23 listing [5] - Analysts are optimistic about the future of the innovative drug sector, citing supportive policies and improvements in the sector's fundamentals as key factors driving the current market momentum [6][7]